Abstract
Gliomas arise in the glial cells of the brain or spine and are the most prevalent and devastating type of brain tumors. Studies of tumor immunology have established the importance of the tumor micro-environment as a driver of oncogenesis. Inflammatory mediators such as IL-1β and IL-18 released by monocytes regulate transcriptional networks that are required for malignant cell growth. Berberine is a natural botanical alkaloid that is widely found in the Berberis species. Although it has been widely used as an anti-diarrheal treatment in North America for several decades, our study is the first to investigate berberine as an anti-tumor agent in glioma cells. In this study, we demonstrate that berberine significantly inhibits inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequent production of IL-1β and IL-18 by glioma cells. Moreover, we found that berberine treatment led to decreased motility and subsequently cell death in U251 and U87 cells. In addition, our study is the first to indicate that berberine can reverse the process of epithelial-mesenchymal transition, a marker of tumor invasion. Taken together, our work supports berberine as a putative anti-tumor agent targeting glioma cells.
Introduction
Gliomas are one of the most prevalent primary intracranial tumors, representing about 81% of malignant brain tumors. Although relatively rare, it usually causes significant mortality and morbidity (). So far, gliomas remain incurable, despite many attempted treatment approaches (). Concomitant loss of chromosomes 1p and 19q is one of the best studied molecular alterations in gliomas and is strongly associated with oligodendroglia morphology and mortality (). In addition, high mutation rates of p53 in gliomas is reported to be responsible for the initiation of rapid glioma growth, which has led researchers to examine this alteration in association with glioma onset (). Bevacizumab, a targeted therapeutic for gliomas, still does not improve overall survival (OS) in either recurrent gliomas or newly-diagnosed gliomas. Thus, novel, effective, targeted therapies for gliomas are in urgent need ().
Inflammation is a key component of the glioma microenvironment. Neuroinflammatory cytokines such as interleukin-1 (IL-1) secreted by glioma cells are known to contribute to tumor initiation and early progression (). The inflammatory response and cancer are highly linked by specific intrinsic pathways, whereby genetic alterations that cause cancer orchestrate the proinflammatory microenvironment, and IL-1 has been associated in this process. For example, IL-1α is a downstream effector of Ras activation and is essential for Nuclear factor-[kappa]B (NF-κB)-regulated gene activation, which includes cytokines and chemokines required for the establishment of a favorable microenvironment for oncogenesis (). A recent phase 2 clinical trial of a recombinant IL-1R antagonist against multiple myeloma demonstrated a favorable safety profile and improved the disease-free rate, providing evidence that anti-IL-1 therapy is an effective therapeutic strategy against cancer ().
Berberine is a compound isolated from a Chinese herb, which has a wide spectrum of pharmacological effects as an anti-cancer, anti-inflammatory, and neuroprotective treatment (). The immunomodulatory effect of berberine that underlies its neuroprotective activities has been well-documented in several preclinical and clinical studies (). For example, the therapeutic effects of berberine on host immune cells such as lymphocytes, leukocytes, astrocytes, and microglial cells in neurological, inflammatory and autoimmune disorders have been well-explored (). Recently, studies have shown berberine can exert antitumor activities both in vitro and in vivo through distinct mechanisms including transcriptional regulation of oncogenes and carcinogenesis-related gene expression, modulation of reactive oxygen species production, mitochondrial transmembrane potential, and NF-κB activation (). Moreover, berberine was found to inhibit tumor growth through cell cycle arrest and apoptosis in various types of tumors, including leukemia, liver cancer, gastric cancer, colon cancer, and breast cancer ().
However, it remains unclear if anti-inflammatory effect of berberine translates into an anti-tumor effect in glioma cells. In this study, we investigated the effects of berberine on glioma cells and further evaluated the underlying mechanisms of berberine-induced anti-tumor activity.
Materials and Methods
Collection of Glioma and Non-tumorous Human Brain Tissues
Human glioma tissues and non-tumorous brain tissues were obtained by surgical removal at the first affiliated hospital of Harbin Medical University. Each glioma sample was graded according to the guideline released by WHO. The study was approved by the ethics committee of Harbin Medical University and written informed consent was obtained from each patient.
Immunohistochemical Analysis
Paraffin sections were heated at 60°C, deparaffinized in xylene, rehydrated in graded ethanol and microwaved for antigen retrieval. Slides were incubated with primary antibodies against caspase-1 (#3866; Cell Signaling Technology, Beverly, MA, USA), IL-18 (10663-1-AP, Proteintech, Wuhan, China), and IL-1β (16806-1-AP, Proteintech, Wuhan, China) at 4°C overnight. Slides were processed for incubation with secondary antibodies for 2 h at room temperature and stained with diaminobenzidine.
Cell Culture and Drug Treatment
Human U87 and U251 cell lines and oligodendrocytes were purchased from American Type Culture Collection. The cells were cultured in DMEM (11965118; Invitrogen, Shanghai, China) supplemented with 10% fetal bovine serum (04-001-1; Biological industries, Beit-Haemek, Israel). For drug treatments, U87 and U251 cells were treated with a specific caspase-1 inhibitor N-Ac-Tyr-Val-Ala-Asp-CMK (Ac-YYAD-CMK) (10014; Cayman Chemical, Ann Arbor, MI, USA) and U0216, a MEK1 and MEK2 inhibitor (U120; Sigma-Aldrich, St. Louis, USA), respectively, at indicated dosage.
MTT Assay
Cell viability was determined by MTT assays according to the manufacturer's instructions. Briefly, cells (2 × 104 cells/well) treated with either berberine or Ac-YVAD-MK were seeded in a 96-well plate. Twenty microliter of MTT solution (88417; Sigma, St. Louis, MO, USA) was added to each well and incubated at 37°C for 4 h followed by dimethyl sulfoxide (DMSO) incubation to dissolve formazine granules. The absorbance at 490 nm was measured using a microplate reader.
Wound Healing Assay
U87 and U251 cells were incubated in a 6-well plate at a confluence of 90%. The cell monolayer was scratched in a straight line with a pipette tip. The wound area was quantified using ImagePro Plus 7.0 software (Media Cybernetics, Rockville, Maryland, USA), and the ratio of the healing area relative to the initial wound area was calculated. Quantification of bands was performed using the ImageJ program (National Institutes of Health, Bethesda, Maryland, USA). Three random fields of view were visualized and photographed using an inverted microscope.
Immunofluorescence Staining
Cells growing on coverslips were rinsed with PBS for 3 × 5 min and then fixed with 4% paraformaldehyde for 30 min. Cells were permeabilized with 0.1% Triton-100 for 15 min followed by three washes with PBS. The coverslips were then blocked with 1% BSA in PBS for 30 min at 37°C and then incubated with primary antibody at a dilution of 1:100 at 4°C overnight. Cells were incubated with FITC-conjugated anti-rabbit IgG (H + L) antibodies. After three washes, the cells were incubated with 1 μg/ml DAPI in PBS for 5 min. The coverslips were observed using an Axiovert 200 (Zeiss) fluorescence microscope.
Enzyme-Linked Immunosorbent Assay (ELISA)
Supernatant was collected for the measurement of IL-1β and IL-18 concentration using ELISA kits (EK0864 and EK0392; Boster, Wuhan, China) according to manufacturer's instructions. Briefly, the supernatant of cell cultures was collected and IL-1β and IL-18 were determined by ELISA. The optical density at 450 nm was determined using the microplate reader Epoch 2 (BioTek).
Real-Time PCR Analysis
Total RNA was extracted using TRIzol reagent (15596018; Invitrogen, Carlsbad, CA, USA) from either brain tissues or U87 cells. First-strand cDNA was synthesized using PrimeScript reverse transcription kit (RR047Q; TaKaRa, Shiga, Japan) according to the manufacturer's instructions. Real-time PCR was carried out with a SYBR Green PCR Master Mix Kit (4309155; Applied Biosystems, CA, USA) and performed on 7500 FAST Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). GAPDH was used as a housekeeping gene.
Western Blot Analysis
Cells were washed with cold PBS and treated with RIPA buffer (89900; Thermo, Rockford, IL, USA) containing protease inhibitor cocktail (4693132001; Roche) and 1% phenylmethylsulfonyl fluoride PMSF (ST505; Beyotime, Shanghai, China). Proteins were quantified by Bradford assay and separated using a 12% SDS-PAGE gel prior to transferring onto a polyvinylidene difluoride (PVDF) membrane. Protein bands were visualized by enhanced chemiluminescence technique using SuperSignal West Pico chemiluminescent substrate (34577; Thermo, CA, USA). Densitometric quantification was performed using ImageJ v1.48 and the relative band intensity for each protein of interest was normalized against GAPDH. The primary antibodies used in this study included antibodies against GAPDH (60004-1-Ig; Proteintech, Wuhan, China), ACTIN (20536-1-AP; Proteintech), caspase-1 (#3866; Cell Signaling), α-catenin (#2131; Cell Signaling), β-catenin (#8480; Cell Signaling), α-SMA (#19245, Cell Signaling), vimentin (#5741; Cell Signaling). The goat anti-rabbit or anti-mouse horse radish peroxidase (HRP)-labeled antibodies were obtained from Proteintech.
Statistical Analysis
Correlations between continuous variables were evaluated by Spearman correlation analysis. The results were expressed as mean ± standard error of mean (mean ± SEM) and analyzed with SPSS 13.0 software. Statistical significance between two individual groups were performed using unpaired Student's t-test. Statistical significance among multiple groups were performed using analysis of variance (ANOVA). A two-tailed p < 0.05 was considered as statistically significant. The survival distributions were described by the Kaplan-Meier survival curve and the log-rank test was used to test the statistical significance. Each experiment has been independently performed at least three times.
Data Collections
A total of 1,510 cases were included in our study: Chinese Glioma Genome Atlas network (CGGA, n = 325, http://www.cgga.org.cn/), The Cancer Genome Atlas (TCGA) mRNA-seq data (n = 699, http://portal.gdc.cancer.gov/), and mRNA-microarray data the Repository for Molecular Brain Neoplasia (Georgetown Database of Cancer G-Doc, http://gdoc.georgetown.edu/gdoc/). Corresponding clinical information were downloaded from public databases, respectively.
Results
IL-1β and IL-18 Expression Is Associated With Clinical and Molecular Characteristics in Gliomas
It is well-established that inflammation within the glioma microenvironment plays a major role in determining the consequence of glioma progression, invasion, and resistance to therapeutic intervention (). We first performed clinical data analysis to determine the association of IL-1β and IL-18 expression with clinical and molecular characteristics in gliomas. Due to the histopathological heterogeneity of gliomas, mRNA levels of IL-1β and IL-18 in gliomas were analyzed according to the WHO grade system and histology. In the TCGA, CGGA, and REMBRANDT datasets, we demonstrated that the expression of IL-1β and IL-18 were significantly increased in grade IV gliomas, compared to those in WHO grade II and grade III gliomas (Figures 1A,D,G). Further, IL-1β and IL-18 expression was significantly increased in mesenchymal gliomas than other types of gliomas (Figures 1B,E,H). Since IL-1β and IL-18 were positively associated with disease progression, we further investigated the prognostic values of IL-1β and IL-18 by Kaplan-Meier analysis. As demonstrated in Figures 1C,F,I, patients with increased expression of IL-1β and IL-18 had significantly shorter survival as compared to other patients. Taken together, these results indicate that increased expression of IL-1β and IL-18 is associated with poor prognostic outcomes for glioma patients.
Figure 1
Expression of Caspase-1, IL-18, and IL-1β Is Significantly Upregulated in Gliomas Compared to Normal Brain Tissues
Since berberine is able to inhibit inflammation both in vitro and in vivo, we first determined the immunogenicity of the gliomas obtained from our center. Caspase-1 is a cysteine protease that activates proinflammatory cytokines IL-18 and IL-1β; thus, we first determined the gene expression and protein level of caspase 1 in clinical samples (). As demonstrated in Figures 2A,B, the protein expression of cleaved caspase-1 (activated form) was significantly increased in glioma tissues as compared to normal brain tissues. Furthermore, we demonstrated that mRNA expression of caspase-1 was also significantly upregulated in glioma tissues compared to normal brain tissues, suggesting that transcriptional upregulation contributes to increased protein expression of cleaved caspase-1 (Figure 2C). Immunohistochemical analysis showed that the expression of IL-18 and IL-1β were significantly upregulated in glioma tissues compared to normal brain tissues (Figures 2D–G). These findings were further confirmed by ELISA. Figures 2H,I show that the protein concentration of IL-18 was 8 times higher in gliomas as compared to normal brain tissues, while the protein concentration of IL-1β was 3 times higher. Mechanistically, the increased protein expressions of IL-18 and IL-1β may also be explained by transcriptional regulation because mRNA levels of IL-18 and IL-1β were significantly increased (Figures 2J,K).
Figure 2
Caspase1 Inactivation Significantly Decreases IL-18 and IL-1β Proteins and Leads to U87 Cell Death
Caspase-1 belongs to a prototypical member of the inflammatory caspases and is responsible for the maturation of pro-interleukin IL-1β and pro-IL-18 (). Downstream of caspase-1, production of IL-1β and IL-18 is highly associated with the status of caspase-1. We first performed a dose-dependent experiment to determine the optimal working concentration of caspase-1 inhibitor, Ac-YYAD-CMK. We found that 50 and 100 μM Ac-YYAD-CMK treatment significantly decreased the protein expression of cleaved caspase-1 (Figures 3A,B), suggesting that the activation of caspase-1 is attenuated. Moreover, we found that the mRNA level of caspase-1 is also significantly downregulated, indicating that the effect is due to transcriptional regulation (Figure 3C). Further, we found that Ac-YYAD-CMK significantly attenuated the release of IL-1β and IL-18 as detected by ELISA, suggesting that the production of IL-1β and IL-18 are regulated by caspase-1 activity (Figures 3D,E). Since our clinical study confirmed that glioma samples have an upregulated protein expression of IL-1β and IL-18, we questioned whether inhibition of the production of IL-1β and IL-18 leads to glioma cell death. We therefore performed the MTT assay to evaluate the potential cytotoxic effect of Ac-YYAD-CMK on U87 cell death. We found that the application of Ac-YYAD-CMK significantly resulted in a profound cell death of U87 cells in a dose-dependent manner (Figure 3F). Furthermore, wound healing experiments showed that Ac-YYAD-CMK significantly attenuated the migration ability of U87 cells, in which decreased closure rates were observed in the wound healing assay (Figures 3G,H).
Figure 3
Berberine Exhibit Inhibitory Effects on Caspase-1, IL-18, and IL-1β Proteins
We next examined if berberine targets IL-18 and IL-1β to mediate its anti-inflammatory effect in U87 cells. We found that protein levels of cleaved caspase-1 were significantly decreased after berberine treatment (Figures 4A,B). QPCR results also demonstrated that berberine treatment led to the downregulation of caspase-1 mRNA, suggesting that berberine may inhibit caspase-1 transcription (Figure 4C). Moreover, berberine treatment resulted in a significant reduction of IL-18 and IL-1β at both the transcriptional and translational levels (Figures 4D-G), suggesting that berberine may regulate the production of IL-18 and IL-1β through inactivation of caspase-1-mediated pathways.
Figure 4
The Potential of Berberine in Glioma Treatment
Considering the fact that berberine significantly attenuates the production of IL-18 and IL-1β, which are normally highly expressed in gliomas, we questioned if berberine treatment would significantly decrease the viability of glioma cells. The MTT assay showed that berberine treatment results in a significant reduction of cell viability of U87 and U251 in a dose-dependent manner, but oligodendrocyte viability was not affected (Figures 5A–C). This suggests that berberine has a specific anti-proliferation effect on glioma cells. Next, we performed wound healing assays to evaluate the effects of berberine on glioma migration. Berberine treatment significantly inhibited cell migration of both U87 and U251 cells (Figures 5D,F). Moreover, wound width was significantly increased after either 50 or 100 μM berberine treatment as compared to control group (Figures 5E,G), suggesting that berberine has an inhibitory effect on cell migration. The phenotype transition of epithelial cells into motile mesenchymal cells, a process called epithelial-mesenchymal transition (EMT), is integral in all aspects of cell biology, including cell development, wound healing, and stem cell behavior. In addition, EMT contributes pathologically to fibrosis and cancer progression (). In cancer biology, it is well accepted that EMT is involved in the generation of invasive cells and acquisition of cancer stem cell properties. Previous reports have demonstrated that berberine can reverse the EMT process in multiple cancer types including cervical cancer, prostate cancer, lung cancer and melanoma (–). We therefore evaluated the effects of berberine on glioma EMT. Using western blots, we showed that berberine treatment significantly increased the protein expression of β-catenin and α-catenin, two markers of the epithelium, and decreased the protein expression of vimentin and α-SMA, two mesenchymal markers in both U87 and U251 cells (Figures 6A–J). Similarly, we found that ~80% of U87 cells treated with berberine exhibited increased staining of β-catenin and decreased staining of vimentin (Figures 6K,L). Taken together, these results suggest that berberine can inhibit the process of EMT.
Figure 5
Figure 6
Berberine Inhibits Caspase-1 Activation via ERK1/2 Signaling Pathway
Next, we used Ac-YYAD-CMK to determine if the inhibitory effect of berberine on EMT is dependent on caspase-1-mediated pathways. Both U87 and U251 cells were treated with Ac-YYAD-CMK and EMT markers were examined as described above. Inhibiting caspase-1 with Ac-YYAD-CMK significantly increased the protein expression of β-catenin and α-catenin, two markers of epithelium, and decreased the protein expression of vimentin and α-SMA, two mesenchymal markers in both U87 and U251 cells (Figures 7A–D), suggesting that berberine inhibits EMT via caspase-1-mediated pathways. It has been reported that berberine induces senescence of human glioma cells by downregulating the extracellular kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway (). As a major mediator of cell invasion and proliferation, aberrant ERK1/2 activation has been shown to be responsible for tumor progression (). We therefore questioned whether the inhibitory effect of berberine on cell viability is mediated by ERK1/2 signaling. Our results showed that berberine treatment on U87 cells significantly decreased the activation of ERK1/2 in a dose-dependent manner (Figures 8A,B). Moreover, we found that inhibiting ERK1/2 signaling using U0216 decreased the protein expression of cleaved caspase-1, suggesting that berberine may regulate caspase-1 activation via ERK1/2 signaling (Figures 8C,D). To further exclude the possibility that berberine halts other signaling pathways that contribute to the inactivation of caspase-1, we examined the effect of berberine on the activation of JNK, p-38 and PI3K pathways. Levels of p-JNK, p-HSP27 and p-Akt did not significantly change after berberine treatment, indicating that neither JNK, p38 nor PI3K pathways participate in the inactivation of caspase-1 (Data not shown). Taken together, our results suggest that berberine may seves as a modulator of ERK1/2 signaling, responsible for both tumor cell death and inactivation of caspase-1-mediated signaling.
Figure 7
Figure 8
Discussion
Berberine is a natural botanical alkaloid that is found in the roots and bark of the Berberis species (). Although the exact mechanisms remain unknown, berberine possesses a variety of biological functions, including anti-diarrheal, anti-fungal, anti-diabetic, hepatoprotective, and cardioprotective effects (). Here, we report that berberine may serve as a potent antitumor agent in glioma therapy. It is well-established that EMT in glioma cells can lead to their acquisition of invasive and metastatic properties (, ). In the current study, we found that berberine significantly increased the expression of β-catenin and decreased the expression of vimentin in U87 and U251 cells. As a result, berberine treatment significantly attenuated cell migration rate, a marker of cancer metastasis. These results together demonstrate an antitumor property of berberine and its clinical potential as an inhibitor of metastasis in glioma cells.
The inflammatory response is a key component of the tumor microenvironment, which is mainly orchestrated by immune cells that are indispensable for tumor proliferation, survival and migration. IL-1β a potent multifunctional pro-inflammatory polypeptide, is usually produced by monocytes and tissue macrophages (). Numerous reports have indicated that IL-1β is produced during inflammation, and this cytokine stimulates tumor cell proliferation and promotes angiogenesis and tumor invasion (). Here, we first demonstrated the stimulatory effect of IL-1β and IL-18 on the migration and invasion of U87 cells. These pro-tumoral effects were significantly inhibited by Ac-YYAD-CMK and berberine. Furthermore, it has been reported that IL-1β promotes glioma migration, invasion, and proliferation with synchronous elevation of MMP-2 and MMP-9 (). IL-1β is a dominant molecule in the hierarchical cytokine signaling cascade in the CNS. Activation of IL-1β-mediated NF-κB leads to the cytoplasmic release and nuclear translocation of NF-κB, which, in turn, controls the expression of inflammatory and oncogenic genes (). On the other hand, it was reported that berberine can inhibit IKK activation, an upstream modulator of the NF-κB pathway. As a result, berberine treatment causes apoptosis of primary effusion lymphoma cells (). Given the importance of IL-1β-mediated intracellular signaling, our study first focused on berberine as a key modulator of tumor microenvironment by targeting IL-1β. We speculated that downstream of IL-1β, NF-κB signaling is likely to be responsible for glioma metastasis and tumor EMT as target genes of NF-κB, such as MMPs and vascular endothelial growth factors, are highly associated with tumor invasion. Similar findings have also been observed in lymphoma. The study found that berberine can inhibit IKK activation and causes efficient apoptosis of primary effusion lymphoma cells. Apart from the NF-κB pathway, our study also demonstrated the effects of berberine on ERK1/2 signaling, which regulates cell proliferation. Targeting the ERK1/2 pathway is a major strategy in a variety of cancer therapeutics. In our study, we found that berberine can significantly inhibit ERK1/2 activation in U87 cells and lead to U87 cell death.
Despite the extensive insights gained in the therapeutic targets in gliomas, there have been no significant benefits obtained from employing such therapies. Our study on berberine has potentially revealed a novel strategy for glioma treatment. Further studies will be conducted to understand the mechanisms by which berberine hampers tumor invasion and the EMT process. Elucidation of pharmacological diversity of berberine is likely to further establish a solid foundation for its application for cancer treatment.
Statements
Ethics statement
This study was carried out in accordance with the recommendations of the ethics committee of Harbin Medical University with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committee of Harbin Medical University.
Author contributions
LT, HQ, and HD designed the studies. CX, YW, YQ, HL, YZ, TX, and HQ performed the experiments. HD, XQ and LT wrote and revised the manuscript.
Funding
This study was supported by the National Natural Science Foundation of China (81700421 to HD,81501050 to HL), the Foundation of Heilongjiang Provincial Postdoctor of China (LBH-Z11076 to LT), the Research Foundation of Education Bureau of Heilongjiang Province (12511176 to LT), and the Science Foundation of Heilongjiang Province for Major Project (ZD2015018 to YW).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- GBM
glioblastoma multiforme
- OS
overall survival
- IL-1
interleukin-1
- IL-1R
interleukin-1 receptor
- CGGA
Chinese Glioma Genome Atlas network
- TCGA
The Cancer Genome Atlas
- REMBRANDT
Repository for Molecular Brain Neoplasia
- EMT
epithelial–mesenchymal transition
- ERK/MAPK
extracellular signal-regulated kinase/mitogen-activated protein kinase
- α-SMA
α-smooth muscle actin
- MMP
matrix metalloproteinase
- NF-κB
nuclear factor kappa B
- DMSO
dimethyl sulfoxide
- ELISA
Enzyme-linked immunosorbent assay
- PVDF
polyvinylidene difluoride
- SEM
standard error of mean
- ANOVA
analysis of variance
- JNK
c-Jun N-terminal kinase
- HSP
heat shock protein.
Abbreviations
References
1.
OstromQTBauchetLFaithG. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. (2014) 16:896–913. 10.1093/neuonc/nou087
2.
LeeSSFyrnerTChenFÁlvarezZSleepEChunDSWeinerJAet al. Sulfated glycopeptide nanostructures for multipotent protein activation. Nat Nanotechnol. (2017) 12:821. 10.1038/nnano.2017.109
3.
SmithJSPerryABorellTJLeeHKO'FallonJHosekSMet al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. (2000) 18:636–45. 10.1200/JCO.2000.18.3.636
4.
ClausEBWalshKMWienckeJKMolinaroAMWiemelsJLSchildkrautJMet al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. (2015) 38:E6. 10.3171/2014.10.FOCUS12367
5.
WangHXuTJiangYXuHYanYFuDet al. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. (2015) 17:239–55. 10.1016/j.neo.2015.02.002
6.
ShalapourSKarinM. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Investig. (2015) 125:3347. 10.1172/JCI80007
7.
MantovaniABarajonIGarlandaC. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. (2018) 281:57–61. 10.1111/imr.12614
8.
NakamuraKSmythMJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol. (2017) 95:325. 10.1038/icb.2016.126
9.
LinTHKuoHCChouFPLuFJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer. (2008) 8:58. 10.1186/1471-2407-8-58
10.
Simões PiresENFrozzaRLHoppeJBMenezes BdeMSalbegoCG. Berberine was neuroprotective against an in vitro model of brain ischemia: survival and apoptosis pathways involved. Brain Res. (2014) 1557:26–33. 10.1016/j.brainres.2014.02.021
11.
WangZChenZChenTYiTZhengZFanHet al. Berberine attenuates inflammation associated with delayed-type hypersensitivity via suppressing Th1 response and inhibiting apoptosis. Inflammation. (2017) 40:221–31. 10.1007/s10753-016-0472-6
12.
SunYXunKWangYChenX. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs. (2009) 20:757. 10.1097/CAD.0b013e328330d95b
13.
LiDZhangYLiuKZhaoYXuBXuLet al. Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth. Lab Investig. (2017) 97:1343. 10.1038/labinvest.2017.71
14.
BoussiotisVACharestA. Immunotherapies for malignant glioma. Oncogene. (2017) 37:1121–41. 10.1038/s41388-017-0024-z
15.
PomerantzBJReznikovLLHarkenAHDinarelloCA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA. (2001) 98:2871–6. 10.1073/pnas.041611398
16.
LamouilleSXuJDerynckR. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. (2014) 15:178–96. 10.1038/nrm3758
17.
ChuSCYuCCHsuLSChenKSSuMYChenPN. Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol Pharmacol. (2014) 86:609–23. 10.1124/mol.114.094037
18.
LiuCHTangWCSiaPHuangCCYangPMWuMHLaiILLeeKH. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance. Int J Med Sci. (2015) 12:63–71. 10.7150/ijms.9982
19.
QiHWXinLYXuXJiXXFanLH. Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis. J Transl Med. (2014) 12:22. 10.1186/1479-5876-12-22
20.
KouYLiLLiHTanYLiBWangKet al. Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells. Biochem Biophys Res Commun. (2016) 479:290–6. 10.1016/j.bbrc.2016.09.061
21.
LiuQXuXZhaoMWeiZLiXZhangXet al. Berberine induces senescence of human glioblastoma cells by downregulating EGFR-MEK-ERK signaling pathway. Mol Cancer Therapeut. (2015) 14:355–63. 10.1158/1535-7163.MCT-14-0634
22.
HanYWuZWuTHuangYChengZLiXet al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. (2016) 7:e2123. 10.1038/cddis.2015.407
23.
TongNZhangJChenYLiZLuoYZuoHet al. Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro. Oncol Lett. (2012) 3:1263–7. 10.3892/ol.2012.644
24.
YanYRXieQLiFZhangYMaJWXieSMet al. Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells. Neuropathology. (2014) 34:128–34. 10.1111/neup.12062
25.
ZhangJCaiHSunLZhanPChenMZhangFet al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res. (2018) 37:225–41. 10.1186/s13046-018-0864-6
26.
CarmichaelMDDavisJMMurphyEACarsonJAVan RooijenNMayerEet al. Role of brain macrophages on IL-1beta and fatigue following eccentric exercise-induced muscle damage. Brain Behav Immun. (2010) 24:564–8. 10.1016/j.bbi.2009.12.011
27.
RmaliKAAl-RawiMAParrCPuntisMCJiangWG. Upregulation of tumour endothelial marker-8 by interleukin-1beta and its impact in IL-1beta induced angiogenesis. Int J Mol Med. (2004) 14:75–80. 10.3892/ijmm.14.1.75
28.
FathimaHKRamaswamyPNandakumarDN. IL-1β microenvironment promotes proliferation, migration, and invasion of human glioma cells. Cell Biol Int. (2015) 38:1415–22. 10.1002/cbin.10353
29.
JungYJIsaacsJSLeeSTrepelJNeckersL. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. (2003) 17:2115–7. 10.1096/fj.03-0329fje
Summary
Keywords
gliomas, berberine, EMT, ERK1/2, IL-1β, IL-18
Citation
Tong L, Xie C, Wei Y, Qu Y, Liang H, Zhang Y, Xu T, Qian X, Qiu H and Deng H (2019) Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release. Front. Oncol. 9:364. doi: 10.3389/fonc.2019.00364
Received
10 December 2018
Accepted
18 April 2019
Published
14 May 2019
Volume
9 - 2019
Edited by
Kuzhuvelil B. Harikumar, Rajiv Gandhi Centre for Biotechnology, India
Reviewed by
Sahdeo Prasad, University of Texas MD Anderson Cancer Center, United States; Prasanna Kumar Santhekadur, JSS Academy of Higher Education and Research, India
Updates
Copyright
© 2019 Tong, Xie, Wei, Qu, Liang, Zhang, Xu, Qian, Qiu and Deng.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haoyu Deng eric.deng@hli.ubc.caHuijia Qiu qiuhuijia@tongji.edu.cn
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
†These authors share co-first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.